Primary HIV-1 Drug Resistance and Polymorphic Patterns Among Injecting Drug Users (IDUs) in Chennai,Southern India

Abstract

Background and Objective: India has 1.1 million injecting drug users (IDUs) with an HIV prevalence rate as high as 64%. Drug resistance screening before therapy is beneficial to the individual. Here, we have studied primary drug resistance among IDUs in Chennai.

Methods: Specimens (n = 55) collected between March 2005 and April 2006 were subjected to genotyping assay. The mutations for the drug resistance were interpreted using the Stanford HIV Drug Resistance Database.

Results: M41LM (1.8%), K65KN (1.8%), and G73GS (2.7%) were found to be associated with low-level resistance to zidovudine (ZDV), stavudine (d4T), abacavir (ABC), didanosine (ddI), emtricitabine (FTC), tenofovir (TDF), and saquinavir (SQV) in each specimen. The rate of polymorphisms is significantly different from universally established subtype ‘‘C’’-specific polymorphisms (P < .0001).

Conclusion: The presence of drug resistance mutations, though minimal, is alarming as it could spread easily between IDUs and from them to their sexual partners. The genetic variation is of importance in vaccine design.

Keywords

HIV-1 injecting drug users primary drug resistance HIV-1 polymorphism

References

UNAIDS/WHO / Report on the global AIDS epidemic. Status of the global HIV epidemic; 2008 . http://www.unaids.org. Accessed August, 2008.

National AIDS Control Organization (NACO), India. HIV sentinel surveillance and HIV estimation in India 2007: a technical brief ; 2009. http://www.nacoonline.org/upload/Publication/M&E%20Surveillance,%20Research/HIV%20Sentinel%20Surveillance%20and%20HIV%20Estimation%202007_A%20Technical%20Brief.pdf. Accessed February, 2009.

Shah B. , Walshe L. , Saple DG , et al. Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India . Clin Infect Dis. 2007;44(9):1235-1244.

Sunil S. , Balakrishnan P. , Shetty N. , et al. Prevalence of treatment failure and drug resistance among treatment-experienced hiv-1-infected individuals at a tertiary HIV referral center in South India . 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA, poster 647.

National AIDS Control Organization (NACO), India. HIV/AIDS epidemiological surveillance & estimation report for the year 2005; 2006. http://www.nacoonline.org/fnlapil06rprt.pdf . Accessed February, 2008.

Solomon SS , Srikrishnan AK , Mehta SH , et al. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern . J Acquir Immune Defic Syndr. 2008;49(3):327-332.

Balakrishnan P. , Kumarasamy N. , Kantor R. , et al. HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses. 2005;21(4):301-305.

Shafer RW , Rhee SY , Pillay D. , et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21(2):215-223.

Kantor R. , Katzenstein DA , Efron B. , et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2(4):e112.

10.

Baxter JD , Schapiro JM , Boucher CA , et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor Tipranavir. J Virol. 2006;80(21):10794-10801.

11.

Palella FJ Jr , Delaney KM , Moorman AC , et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection . N Engl J Med. 1998; 338(13):853-860.

12.

Pujari S. , Patel A. , Joshi SR , et al. Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008). J Assoc Physicians . 2008;56:339-348, 353-371.

13.

Stanford University. HIV drug resistance database. A curated database designed, to represent store and analyze the divergent forms of data underlying HIV drug resistance. Mutation List Analysis. http://hivdb6.stanford.edu/asi/deployed/hiv_central.pl?program=hivdb&action=showMutationForm. Accessed April 15, 2008.

14.

Kozal MJ , Amico KR , Chiarella J. , et al. HIV drug resistance and HIV transmission risk behaviors among active injection drug users. J Acquir Immune Defic Syndr. 2005;40(1):106-109.

15.

Salomon H. , Wainberg MA , Brenner B. , et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS. 2000;14(2):F17-F23.

16.

Sethi AK , Celentano DD , Gange SJ , Gallant JE , Vlahov D. , Farzadegan H. High-risk behavior and potential transmission of drug-resistant HIV among injection drug users. J Acquir Immune Defic Syndr. 2004;35(5):503-510.

17.

Maia Teixeira SL , Bastos FI , Hacker MA , Guimarães ML , Morgado MG Trends in drug resistance mutations in antiretroviral-naïve intravenous drug users of Rio de Janeiro. J Med Virol. 2006;78(6):764-769.

18.

Liao L. , Xing H. , Li X. , et al. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 isolates from recently infected injecting drug users in western China. AIDS Res Hum Retroviruses. 2007;23(8):1062-1065.

19.

Kantor R. , Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution . AIDS Rev. 2003;5(1):25-35.